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Over the past decade there has been considerable interest in the assembly of
conjugate toxin molecules whose action is directed toward specific target cells.
A wide variety of cell surface-directed ligands (e.g., mAbs, lectins, polypeptide
hormones, growth factors) have been coupled through disulfide linkage to
nontoxic fragments of plant and/or microbial toxins (reviewed in 1, 2). In
particular, mAbs have been used to direct the cytotoxic action ofricin, both the
A chain and intact toxin, and fragments of diphtheria toxin to specific antigen-
bearing cells. This class ofconjugate toxins are widely known as immunotoxins,
and have been the subject ofseveral recent reviews (3-6).
In contrast to chemical cross-linking to form conjugate toxins, our approach
to the development oftargeted toxins has involved genetic assembly of chimeric
toxin genes that are expressed from recombinant strains ofEscherichia coli K12
(6, 7). We have selected targeting ligands whose cell surface receptors are known
to undergo obligatory receptor-mediated endocytosis in the design of chimeric
toxins that are composed of portions of diphtheria toxin linked to peptide
hormones and/or growth factors. We have used rDNA methodologies to con-
struct fusion genes in which that portion ofthe diphtheria toxgene which encodes
the receptor-binding domain has been genetically replaced with the cDNA
encoding the ligand of choice. Murphy et al. (6) and Williams et al. (7) have
described the genetic construction of fusion toxins in which a-melanocyte-
stimulating hormone (a-MSH)' and IL-2 have served as the receptor-binding
component ofthe hybrid. Since both peptides have been shown to bind to surface
receptors and are internalized by receptor-mediated endocytosis (8-10), we
reasoned that both a-MSH toxin and IL-2 toxin should be selectively toxic for
a-MSH and high affinity IL-2-R-bearing cells, respectively. Indeed, the action
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' Abbreviations used in this paper:
￿
a-MSH, a-melanocyte-stimulating hormone; IC5o, 50% inhibi-
tion of protein synthesis.
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TABLE I
Eukaryotic Cell Lines Used in This Study
ALL, acute lymphoblastic leukemia; ATCC, American Type Culture Collection; ATL, adultT cell
leukemia; CML, chronicmyelogenous leukemia.
of these two chimeric toxins has been shown to be targeted to those cell lines
that express the appropriate receptor. In each instance, cell lines that do not
express the targeted receptor have been found to be resistant to the action ofa-
MSH toxin- or IL-2 toxin-mediated inhibition of protein synthesis.
In the present report, we demonstrate that the cytotoxic action of IL-2 toxin
is mediated through the high affinity IL-2-R on both human and murine T cell
lines in vitro. Since the action of IL-2 toxin is blocked by chloroquine, we
conclude that after binding to IL-2-R and internalization, this chimeric toxin
must pass through an acidic compartment to deliver its ADP-ribosyl transferase
tothe T cell cytosol. Finally, we demonstrate that IL-2 toxin-mediated inhibition
of protein synthesis in high affinity IL-2-R-positive leukemic cell lines results
from the classic diphtheria toxin fragment A-catalyzed ADP ribosylation of
elongation factor 2.
Materials and Methods
IL-2 Toxin.
￿
IL-2 toxin was purified from periplasmic extracts of E. coli(pAB1508) as
previously described (7).
Cell Culture.
￿
The eukaryotic cell lines used in this study are listed in Table I. C91/PL
cells (11), derived from HTLV-I-transfected cord blood T lymphocytes, were cultured
in RPMI 1640 medium supplemented with 15% FCS and 2 mM glutamine. Cells were
subcultured at 3-4-d intervals. The IL-2-dependent murine CTLL-2 cell line (TIB-214;
American Type Culture Collection, Rockville, Maryland) was maintained under similar
conditions except that the medium was supplemented with 10% heat-inactivated FCS, 25
mM Hepes, 2 mM glutamine, and 40% rat T cell growth factor (12). All other cell lines
used in this studywere maintained in RPMI medium supplemented with 15% FCS and 2
mM glutamine.
Cytotoxicity Assays.
￿
Cells were seeded in 96-well V-bottomed plates (Nunc, Roskilde,
Denmark) at a concentration of l0"/well (CTLL-2) or 105/well in 100 JAI complete
medium . Diphtheria toxin (Connaught Laboratories Ltd., Toronto, Canada)or IL-2 toxin
at varying concentrations (10-'2-10-s M) in complete medium was added. Cells cultured
with medium alone were included as the control. After a 24-h incubation at 37°C under
Cell line Species Tissue type IL-2-11 Source or reference
C91/PL Human Cord T cell HTLV-I + 11
transformed
C10/MJ Human Cord T cell HTLV-I + 11
transformed
MT-2 Human Cord T cell HTLV-I + 41
transformed Robert Schwartz (Tufts
Medical School)
Hut 102/6TG Human T cell (ATL) + KendallSmith (Dart-
mouth MedicalSchool)
CTLL-2 Murine T cell (cytotoxic) + 42
ATCC (TIB 214)
CEM-EM3 Human T cell (ALL) - ATCC (TIB 195)
CCRF HSB-2 Human T cell (ALL) - ATCC (CCL 120.1)
K562 Human Granulocyte (CML) - ATCC (CCL 243)O h
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￿
Inhibition of protein
synthesis in IL-2-R-positive hu-
man C91/PL Tcellsby IL-2 toxin
(t)and diphtheria toxin (O). Val-
uesare expressed as a percentage
of ["Clleucine incorporation by
untreated controls.
5% C02, the plates were centrifuged for 5 min at 200 g, the medium was removed and
replaced with 100 ul leucine-free medium (DMEM Selectamine; Gibco, Grand Island,
NY) containing 2.5,uCi/ml ["C]leucine (New England Nuclear, Boston, MA). Cells were
then incubated at 37°C for 90 min and then collected on glass fiber filters using a cell
harvester (Skatron Inc., Sterling, VA). Filters were washed, dried, and counted according
to standard methods. All experiments were performed in quadruplicate.
Determination ofElongation Factor 2 Levels AvailableforADP Ribosylation.
￿
The levelof
elongation factor 2 that was available for ADP ribosylation was determined essentially as
described by Moynihan and Pappenheimer (13). Cells were seeded in 24-well plates at a
concentration of 5 x 105/well in 1 ml of medium . Diphtheria toxin or IL-2 toxin was
added to the wells in 100 Ecl medium. After a 24-h incubation, the cell suspension was
transferred to microcentrifuge tubes and centrifuged for 4 min. The cell pellets were
lysed and assayed for the level of elongation factor 2 available for ADP ribosylation by
the addition of purified diphtheria toxin fragment A to 2 jug/ml and [12P]NAD to 1-2
Ci/ml. Assays were performed in triplicate.
Results
IL-2 Toxin Inhibition of Protein Synthesis in IL-2-R-positive Cells.
￿
Williams et
al. (7) demonstrated that immunoaffinity-purified IL-2 toxin inhibits protein
synthesis in a variety of IL-2-R-positive cell lines; whereas IL-2-R-negative cell
lines were found to be uniformly resistant. We have now characterized the
sensitivity of several HTLV-I-infected human T cell lines to IL-2 toxin by close-
response analysis. As shown in Fig. 1, exposure of human C91/PL T cells to IL-
2 toxin at a concentration of 5 X 10- " M for 24 h results in a 50% inhibition of
protein synthesis (IC5o), compared to untreated control cultures. It is of interest
to note that the ICbo for native diphtheria toxin in the C91/PL T cell line is 4 X
10-s M . Moreover, similar results were obtained in dose-response analysis of
both IL-2 toxin and diphtheria toxin using the high affinity IL-2-R-positive
C10/MJ, MT-2, and HUT 102/6TG T cell lines in vitro (data not shown).
Eukaryotic cell lines of murine origin are markedly resistant to diphtheria
toxin even though their elongation factor 2 is sensitive to ADP ribosylation in
vitro (14). Since the CTLL-2 murine T cell line expresses high affinity, growth-
promoting IL-2 receptors, it was of interest to examine the sensitivity of these
cells to IL-2 toxin. As depicted in Fig. 2, the IC50 for IL-2 toxin is ^-2 X 10- ' °100
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Inhibition of protein
synthesis in IL-2-R-positive mu-
rine CTLL-2 Tcells by IL-2 toxin
(0) anddiphtheria toxin (O). Val-
uesareexpressedas apercentage
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FIGURE 3.
￿
Inhibition of protein
synthesis in IL-2-R-negative
CEM-EM3 (O) and CCRF HSB-2
(0) human T cells, and the K562 J
￿
40
￿
(O) human granulocyte cell line.
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M. In striking contrast, concentrations ofdiphtheria toxin as high as 10-6 M fail
to inhibit protein synthesis in CTLL-2 cells in vitro.
Williams et al. (7) have shown that several eukaryotic cell lines that are devoid
of the high affinity IL-2-R are resistant to the action of IL-2 toxin. We have
extended this observation toa total of22 different eukaryotic cell linesofhuman,
monkey, murine, rat, hamster, and feline origin. Fig. 3 shows representative IL-
2 toxin dose-response curves for three different IL-2-R-negative cell lines. The
inhibition of protein synthesis observed at higher concentrations of IL-2 toxin
are likely to result from nonreceptor site-specific fluid phase uptake into endo-
cytic vesicles. Indeed, similar dose-response curves are seen in the case of the
ADPR-transferase-positive, receptor-binding domain-negative CRM45 mutant
ofdiphtheria toxin (15).
IL-2-R-mediated Toxicity. To demonstrate that the action of IL-2 toxin is
mediated by IL-2-R, the effect of a number of competitive and noncompetitive
inhibitors ofIL-2-R site binding were examined . As shown in Table 11, incubation
ofC91/PL cells in the presence of 4 X 10-9 M IL-2 toxin for 24 h inhibits [I4C]
leucine incorporation to 14% of control levels. Addition ofexcess free rIL-2 to
the incubation mixture completely blocks the inhibitory effect of IL-2 toxin on616
￿
INTERLEUKIN 2 RECEPTOR-TARGETED TOXICITY
TABLE II
Incorporation of["C]Leucine by Human C91/PL IL-2-R+ T Cells
after a 24-h Exposure to IL-2 Toxin
* mAbto IL-2-R.
tmAbto theearly activation antigen 4F2.
leucine incorporation byC91/Pl cells. In addition, coincubation withthe 33113.1
anti-IL-2-R mAb (16), which binds to the p55 subunit of the IL-2-R, was found
to partially block the action of IL-2 toxin. In direct contrast, coincubation with
agents that interact with cell surface structures other than IL-2-R (e.g., transfer-
rin, mAb 4F2 directed towards an early activation antigen on the Tcell surface,
and antithrombospondin) have no effect on IL-2 toxin-mediated inhibition of
protein synthesisin C91/PL cells in vitro. We have found that rIL-2 competitively
blocks the action ofIL-2 toxin on murine CTLL-2 T cells, while transferrin has
no effect (data not shown) . mAbs to murine IL-2-R (e.g., M7/20 [reference
17]) themselves inhibit the growth of CTLL-2 cells in vitro; therefore, this
receptor-binding control was not performed.
IL-2 Toxin Internalization. After binding to specific receptors on the cell
surface, diphtheria toxin is concentrated in coated pits and internalized by
receptor-mediated endocytosis (18, 19). Many ligands thatentercells by receptor-
mediated endocytosis can be detected in vesicles that rapidly become acidified.
Indeed, acidification of the vesicle is essential for the membrane translocation of
fragment A of diphtheria toxin to the cytosol (20-22). A wide variety of
lysosomotropic agents that preventacidification oftheendosome blocks diphthe-
rial intoxication (23). To further characterize the mechanism by which IL-2
toxin inhibits protein synthesis in high affinity IL-2-R-bearing T cells, we have
found that theaddition ofchloroquine completely blocks the action ofIL-2 toxin
onC91/PL T cells in vitro (Table III) and murine CTLL-2 cells (datanot shown).
Hence, after binding to IL-2-R and internalization, IL-2 toxin must pass through
an acidic vesicle in order to deliver its ADP ribosyl transferase to the cytosol.
IL-2 Toxin ADP-ribosylates Elongation Factor 2. Diphtheria toxin-mediated
inhibition of protein synthesis in sensitive eukaryotic cells involves the fragment
A-catalyzed ADP ribosylation of elongation factor 2 (15). Since it is possible,
albeit unlikely, that IL-2 toxin-mediated inhibition of['4C]leucine incorporation
in high affinity IL-2-R-bearing T cells may have been due to stearic hindrance
of the receptor, we have directly measured the elongation factor 2 that was
available for ADP ribosylation in C91/PL and CTLL-2 cells that were exposed
to either diphtheria toxin or IL-2 toxin. As shown in Table IV, murine CTLL-
2 T cells that are resistant to diphtheria toxin, but sensitive to IL-2 toxin, have
IL-2 toxinconcentra-
tion
M
Addition (10' M) Control incor-
poration
- - 100
4 x 10-9 - 14
4 x 10-9 IL-2 111
4 x 10-9 3311.3* 72
4 x 10-9 Transferrin 17
4 x 10-9 4F2* 15TABLE III
Incorporation of['4C]Leucine by C91/PL Cells after Exposure to IL-
2 Toxin in the Presence and Absence ofChloroquine
BACHA ET AL.
Chloroquine wasaddedto a final concentration of6 X 10-6 M; IL-2 toxin
wasaddedto a finalconcentration of 1 X 10-9 M.
TABLE IV
Murine CTLL-2 andHuman C91/PL Elongation Factor 2Available
for ADP-ribosylation after 24-h Exposure to Either Diphtheria
Toxin or IL-2 Toxin
Discussion
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reduced levels ofelongation factor 2 available for ADP ribosylation after a 24-h
incubation with IL-2 toxin. As expected, incubation of CTLL-2 cells with 10-7
M diphtheria toxin for 24 h fails to inhibit protein synthesis and does not result
in reducing the level of elongation factor 2 available for ADP ribosylation. In
the case of human C91/PL T cells, which are sensitive to both diphtheria toxin
and IL-2 toxin, reduced levels of elongation factor 2 available for ADP ribosy-
lation were found after incubation with either toxin. Moreover, since the growth
of C91/PL cells in vitro is IL-2 independent, we conclude that the inhibition of
target cell protein synthesis is mediated through the action of IL-2 toxin rather
than nonspecific stearic hindrance of IL-2-R.
We have used protein engineering and DNA techniques for the genetic
assembly ofa fusion gene in which thediphtheria toxin receptor-binding domain
has been replaced with IL-2 sequences (7). This genetic construction is analogous
to a previous report in which the diphtheria toxin receptor-binding domain has
been replaced with the a-MSH (6). The chimeric IL-2 toxin has been found to
be selectively toxic for only those eukaryotic cell lines that bear high affinity
surface receptors for IL-2. In the present report, we have demonstrated that IL-
2 toxin is specifically targeted toward IL-2-11 on a variety of HTLV-I-infected
transformed human Tcell lines, as well as the IL-2-dependent murine CTLL-2
Control level
Cell line Toxin and concentration of EF-2 avail-
able for ADP
ribosylation
CTLL-2 Diphtheria (10' M) 98
IL-2 toxin (10-8 M) 8
C91/PL Diphtheria (10-6 M) <5
IL-2 toxin (10-8 M) <5
["C]Leucine incorporation
Addition
cpm ± SEM % Control
None 36,136 ± 724 100
Chloroquine 30,553 t 453 84
IL-2 toxin 13,692 ± 333 38
IL-2 toxin + chloroquine 27,543 ± 855 9061 8
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T cell line. In both instances, IL-2 toxin-mediated inhibition ofprotein synthesis
in target T cells can be blocked by agents which bind to the IL-2-R; e.g., a molar
excess of rIL-2 or anti-IL-2-R mAb. In contrast, agents that bind to other cell
surface receptors, or mAbs that bind to other early lymphocyte activation
antigens, do not block IL-2 toxin-mediated inhibition ofcellular protein synthe-
sis. In addition, we have shown that chloroquine completely blocks the cytotoxic
action of both diphtheria toxin and IL-2 toxin. These results strongly suggest
that IL-2 toxin, like diphtheria toxin (20-22), must be internalized and pass
through an acidic vesicle in order to deliver its ADP ribosyl transferase to the T
cell cytosol.
Once IL-2 is bound to its high affinity receptor it has been shown to be rapidly
internalized (24); in addition, recent evidence suggests that the high affinity IL-
2-R is not recycled (25). Two cell surface proteins that bind IL-2 have been
characterized: a 55,000- and a 70,000-dalton glycoprotein. The Tac antigen, the
55,000-dalton low affinity IL-2-binding protein (p55), has been defined by many
mAbs including 33113.1 (16), and in the case of the murine IL-2-R, M7/20 (17);
however, interaction ofIL-2 or anti-IL-2-R mAbs with the p55 subunit does not
readily promote internalization of the ligand (9, 10). Moreover, interaction of
IL-2 with the p55 low affinity receptor does not stimulate DNA synthesis (26,
27). The 70,000-dalton subunit ofIL-2-R has been identified and shown to bind
IL-2 with moderate affinity (28-32). A recent report suggests that IL-2 bound
to the p70 subunit is internalized into the cell (33). Given these observations, it
is ofinterest to note that IL-2 toxin is selectively cytotoxic for only those T cell
lines that bear high affinity (p55 + p70) IL-2-R (C. Waters, unpublished obser-
vations).
The only reaction that diphtheria toxin fragment A is known to catalyze in
the eukaryotic cell cytosol is the ADP ribosylation of elongation factor 2 (15).
Moynihan and Pappenheimer (13) have shown that fragment A oftoxin is rapidly
delivered across the cell membrane, and the rate of ADP ribosylation of elon-
gation factor 2 increases with increasing concentrations oftoxin. We have shown
that the IL-2 toxin-mediated inhibition of protein synthesis in both murine
CTLL-2 and human C91/PL Tcells primarily results from ADP ribosylation of
elongation factor 2. This observation demonstrates that the inhibition ofprotein
synthesis in high affinity IL-2-R-bearing Tcells results from the toxin fragment
A-catalyzed reaction, and not from simply blocking the IL-2-R, from the action
of IL-2 itself.
It is of particular interest to note that IL-2 toxin is active against the murine
CTLL-2 T cell line. Cell lines derived from diphtheria toxin-resistant species
(e.g., mouse and rat) are resistant to diphtheria toxin (15). Since elongation
factor 2 derived from these cells is sensitive to ADP ribosylation by fragment A
in vitro, it is not known whether the resistance of whole cells is due to a
nonfunctional diphtheria toxin receptor, a defect in the internalization of diph-
theria toxin, or alternatively to a defect in a putative processing event that may
be involved in the intoxication process. Sensitivity of murine CTLL-2 cells to
IL-2 toxin clearly demonstrates that the binding ofthis diphtheria toxin-related
fusion protein to a receptor that is known to be capable of ligand binding and
subsequent internalization results in the entry of the ADP ribosyl transferase ofBACHA ET AL.
￿
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IL-2 toxin into the cytosol. These results suggest that the diphtheria toxin
receptor on murine cells is either not present or is not functional. The small
decrease in sensitivity of CTLL-2 cells (ICS, 2 X 10-'° M) to IL-2 toxin relative
to human C91/PL Cells (ICS, 5 X 10-" M) may be related to the decreased
affinity ofthe human IL-2 component ofthe fusion protein for the murine IL-2
receptor, or to low levels ofrequisite IL-2 in the medium.
There are several factors that make the high affinity IL-2-R an attractive
target forcytoxic therapeuticagents. The cellulardistribution ofthe high affinity
heterodimeric p55/p70 IL-2-R appears to be largely limited to activated prolif-
erating T lymphocytes, some recently activated B cells, and perhaps activated
macrophages (26, 27, 34, 35). Hematopoietic stem cells do not express the high
affinity IL-2-R, and only rare "resting" or memory Tcells appear to do so (36).
Since the expression of IL-2 and high affinity IL-2-Rs marks a critical and
pivotal event in the development of the immune response, it has been of
considerable interest to examine the therapeutic effectiveness ofmAbs directed
against this receptor. In the case ofboth mAbs that recognize the IL-2-R on the
surface ofmurine T cells (M7/20) and rat T cells (ART 18), a single I0-d course
of therapy was found to greatly extend allograft survival (37, 38). Moreover,
after treatment, immunologic tolerance was often noted. In addition, Kelley et
al. (39) have shown that treatment with anti-IL-2-R mAbs are immunosuppres-
sive in a delayed type hypersensitivity model in the mouse.
In the case of HTLV-I-associated adult T cell leukemia, the 42,000-mol-wt
transactivator, tat, gene product appears to induce the expression of large
numbers of high affinity IL-2-Rs on the leukemic cell surface (40). We have
shown that IL-2 toxin is extremely selective and potent (IC5o ranging between
10 and 50 pM) against a number of human T cell lines in vitro. As such, IL-2
toxin is currently being developed as a prototype biologic agent for the treatment
ofadult Tcell leukemia and other IL-2-R-bearing malignancies.
Summary
The IL-2 toxin-mediated inhibition ofprotein synthesis in high affinity IL-2-
R-positive murine and human T cell lines has been examined . Both excess free
IL-2 and mAb to the Tac epitope of the p55 subunit of IL-2-R are shown to
block the action ofIL-2 toxin; whereas, agents that interact with other receptors
or antigens on the T cell surface have no effect. We show that IL-2 toxin, like
diphtheria toxin, must pass through an acidic vesicle in order to intoxicate target
T cells. Finally, we demonstrate that the IL-2 toxin-mediated inhibition of
protein synthesis in both human and murine T cells that bear the high affinity
IL-2-R is due to the classic diphtheria toxin fragment A-catalyzed ADP ribosy-
lation of elongation factor 2.
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